Pall Debuts Five New Products for Increased Drug Manufacturing Efficiency at INTERPHEX 2005

Business Wire, April 26, 2005

EAST HILLS, N.Y. -- Pall Corporation (NYSE:PLL) introduces five innovative technologies aimed at increasing drug manufacturing efficiency through customization and disposability at INTERPHEX 2005 today. The new technologies deliver a combination of benefits that help drug manufacturers enhance throughput and scalability, eliminate time-consuming steps, shorten processing times and reduce labor. By enabling significant time and cost benefits at multiple points within drug production processes, the new products will help meet the needs of the fast-growing, global biopharmaceuticals industry. The biopharmaceuticals market generated revenues of $45 billion in 2004 and is predicted to reach $98.2 billion by 2011. E[acute accent]"The nature of the biopharmaceutical industry requires constant innovation to address rapidly changing process needs as new classes of drugs are discovered and developed," says Ken Frank, President of Pall BioPharmaceuticals. "The scope of products we are launching at Interphex reinforces our commitment to providing total fluid management across the wide range of biopharmaceutical applications."

E[acute accent]Super-Efficient Chromatography

E[acute accent]The Company is unveiling an innovative chromatography technology for super-efficient capture of large molecules, especially used to develop DNA and virus-based drugs. The Mustang(R) XT5000 capsule answers the industry's need for greater throughput, superior binding capacity and fast processing in a capsule format for use in a wider range of process chromatography applications. E[acute accent]This next-generation ion exchange membrane capsule extends Mustang chromatography's uses beyond removal of contaminants such as DNA, viruses, endotoxins and host cell proteins. It enables super-efficient capture of large molecules, a growing need with the increasing development of new drugs and therapies that utilize recombinant proteins, plasmids and other viral vectors and blood plasma fractions. With the ability to process large fluid volumes 30 times faster than traditional chromatography resins during capture and polishing steps, the new capsule brings the benefits of Mustang technology to both ends of the process chromatography spectrum.

E[acute accent]Single-Use Technologies

E[acute accent]The Company is also introducing two new additions to its growing portfolio of technologies for disposable processing. It is launching the first customizable Tangential Flow Filtration (TFF) system that incorporates single-use components for downstream processing applications. The new mobile TFF system will help manufacturers realize significant time, cost and safety benefits in biopharmaceutical production. E[acute accent]The Kleenpak(TM) Connector, a new single-use device, enables aseptic connections to be made instantly, in a matter of seconds. Capable of withstanding autoclave steam temperatures up to 130 degrees centigrade (130 degrees C), it provides process efficiency for an even broader range of biopharmaceutical applications. It is the only aseptic connector that does not require laminar flow hoods or other capital equipment to make a connection. The disposable device also promotes more efficient manufacturing practices by eliminating the need for cleaning and cleaning validation.

E[acute accent]High Performance Depth Filtration

E[acute accent]Responding to the growing need for higher performance depth filtration, Pall is also launching the SUPRAdisc(TM) HP depth filter. The new filter enables more efficient cell harvest and clarification steps for drug processing with an expanded range of pharmaceutical grade filtration media. The SUPRAdisc HP filter offers higher dirt holding capacity and longer service life compared to other depth filtration systems, addressing the industry's needs to remove the widely varying particle sizes inherent in biotechnology and pharmaceutical drug production.

E[acute accent]Process Simplification

E[acute accent]Also at INTERPHEX 2005, the Company unveils its latest version of operating software that simplifies operation of complex systems. By allowing engineers to make process changes to TFF systems themselves, this software option avoids time-consuming and costly steps associated with reprogramming and revalidation. Its modular design, user-friendly touch screen and pull-down menu further simplify control of critical biopharmaceutical processes.

E[acute accent]About Pall Corporation

E[acute accent]Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2004 were $1.8 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world.